CytoAgents presents preclinical data on CTO1681 for atopic dermatitis
CytoAgents announced the presentation of new preclinical data for CTO1681, an oral immunomodulatory therapy, at the 2026 European Academy of Dermatology and Venereology Congress. The data suggest CTO1681 suppressed multiple proinflammatory cytokines implicated in atopic dermatitis.